Episode Details
Back to Episodes
262: Merck v. USA, the best of ASCO, and Leqembi at the FDA
Published 3 years, 4 months ago
Description
STAT Washington correspondent Rachel Cohrs joins us to explain Merck's lawsuit against the federal government and why the company believes drug pricing negotiation is “tantamount to extortion." We also discuss the health effects of Canadian wildfires, the highlights of the year’s biggest cancer research conference, and what could be a watershed moment in the treatment of Alzheimer’s.